Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Correspondence
  • Published:

ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1

References

  1. Tauchi T, Broxmeyer HE . BCR-ABL signal transduction Int J Hematol 1995 61: 105–112

    Article  CAS  Google Scholar 

  2. Sausville EA . A BCR-ABL kinase antagonist for chronic myelogenous leukemia: a promising path for progress emerges Nature 1999 91: 102–103

    CAS  Google Scholar 

  3. Druker BJ, Tamura S, Buchdunger E, Ohno S, Segal GM, Fanning S, Zimmerman J, Lydon NB . Effects of a selective inhibitor of the abl tyrosine kinase on the growth of BCR-ABL positive cells Nat Med 1996 2: 561–566

    Article  CAS  Google Scholar 

  4. le Coutre P, Mologni L, Cleris L, Marchesi E, Buchdunger E, Giardini R, Formelli F, Gambacorti-Passerini C . In vivo eradication of human BCR-ABL-positive leukemia cells with an ABL kinase inhibitor J Natl Cancer Inst 1999 91: 163–168

    Article  CAS  Google Scholar 

  5. Topaly J, Zeller WJ, Fruehauf S . Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells Leukemia 2001 (in press)

  6. Hehlmann R . Trial of IFN or STI571 before proceeding to allografting for CML? Leukemia 2000 14: 1560–1562

    Article  CAS  Google Scholar 

  7. Nishimaki J, Miyazawa M, Yaguchi M, Katagiri T, Kawanishi Y, Toyama K, Ohyashiki K, Hashimoto S, Nakaya K, Takiguchi T . Vitamin K2 induces apotosis of a novel cell line established from a patient with myelodysplastic syndrome in blastic transformation Leukemia 1999 13: 1399–1405

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Nakajima, A., Tauchi, T. & Ohyashiki, K. ABL-specific tyrosine kinase inhibitor, STI571 in vitro, affects Ph-positive acute lymphoblastic leukemia and chronic myelogenous leukemia in blastic crisis. Leukemia 15, 989–990 (2001). https://doi.org/10.1038/sj.leu.2402137

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2402137

This article is cited by

Search

Quick links